{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:24:08Z","timestamp":1786562648031,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:00:00Z","timestamp":1538092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40257-018-0388-z","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T05:13:13Z","timestamp":1538111593000},"page":"879-886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)"],"prefix":"10.1007","volume":"19","author":[{"given":"Sanminder","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Kalb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke M. G. J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Shear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Langholff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,28]]},"reference":[{"key":"388_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377\u201385.","journal-title":"J Invest Dermatol."},{"key":"388_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","volume":"13","author":"T Henseler","year":"1985","unstructured":"Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"388_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjd.12387","volume":"169","author":"YE Zhao","year":"2013","unstructured":"Zhao YE, Ma JX, Hu L, Xiao SX, Zhao YL. Meta-analysis of the association between psoriasis and human leukocyte antigen-B. Br J Dermatol. 2013;169:417\u201327.","journal-title":"Br J Dermatol"},{"key":"388_CR4","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1067\/mjd.2002.120470","volume":"46","author":"C Ferrandiz","year":"2002","unstructured":"Ferrandiz C, Pujol RM, Garcia-Patos V, Bordas X, Smandia JA. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002;46:867\u201373.","journal-title":"J Am Acad Dermatol"},{"key":"388_CR5","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/bjd.13865","volume":"173","author":"CEM Griffiths","year":"2015","unstructured":"Griffiths CEM, Christophers E, Szumski A, Jones H, Mallbris L. Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis. Br J Dermatol. 2015;173:1271\u20133.","journal-title":"Br J Dermatol"},{"key":"388_CR6","first-page":"1210","volume":"11","author":"KA Papp","year":"2012","unstructured":"Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11:1210\u20137.","journal-title":"J Drugs Dermatol"},{"key":"388_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.13013","volume":"171","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, Leonardi C, Stahle M, Gulliver W, Chevrier M, Fakharzadeh S, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014;171:137\u201347.","journal-title":"Br J Dermatol"},{"key":"388_CR8","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1111\/bjd.16197","volume":"178","author":"LJ Vugt van","year":"2018","unstructured":"van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ. A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis. Br J Dermatol. 2018;178:e80.","journal-title":"Br J Dermatol"},{"key":"388_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.15761\/GOD.1000142","volume":"2","author":"WP Gulliver","year":"2015","unstructured":"Gulliver WP, Young H, Gulliver S, Randell S. HLA-Cw6 status predicts efficacy of biologic treatments in psoriasis patients. Glob Dermatol. 2015;2:228\u201331.","journal-title":"Glob Dermatol."},{"key":"388_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/bjd.12425","volume":"169","author":"E Gallo","year":"2013","unstructured":"Gallo E, Cabaleiro T, Roman M, Solano-Lopez G, Abad-Santos F, Garcia-Diez A, et al. The relationship between tumour necrosis factor (TNF)-\u03b1 promoter and IL12B\/IL-23R genes polymorphisms and the efficacy of anti-TNF-\u03b1 therapy in psoriasis: a case-control study. Br J Dermatol. 2013;169:819\u201329.","journal-title":"Br J Dermatol"},{"key":"388_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/bjd.13056","volume":"171","author":"HY Chiu","year":"2014","unstructured":"Chiu HY, Wang TS, Chan CC, Cheng YP, Lin SJ, Tsai TF. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12\/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol. 2014;171:1181\u20138.","journal-title":"Br J Dermatol"},{"key":"388_CR12","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.jid.2016.06.631","volume":"136","author":"K Li","year":"2016","unstructured":"Li K, Huang CC, Randazzo B, Li S, Szapary P, Curran M, et al. HLA-C*06:02 allele and response to IL-12\/23 inhibition: results from the ustekinumab phase 3 psoriasis program. J Investig Dermatol. 2016;136:2364\u201371.","journal-title":"J Investig Dermatol."},{"key":"388_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/bjd.12331","volume":"169","author":"M Talamonti","year":"2013","unstructured":"Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B\/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12\/23 blocker ustekinumab. Br J Dermatol. 2013;169:458\u201363.","journal-title":"Br J Dermatol"},{"key":"388_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/09546634.2012.755258","volume":"25","author":"V Lernia Di","year":"2014","unstructured":"Di Lernia V, Ficarelli E. Current therapeutic approaches of psoriasis are affected by age at disease onset. J Dermatol Treat. 2014;25:15\u20137.","journal-title":"J Dermatol Treat."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-018-0388-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0388-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0388-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T22:12:57Z","timestamp":1569622377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-018-0388-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,28]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1007\/s40257-018-0388-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,28]]},"assertion":[{"value":"28 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by Janssen Scientific Affairs, LLC, Horsham, PA, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"S. Singh has no conflicts of interest. R. E. Kalb has received grants and\/or research funding from AbbVie, Amgen, Janssen, Merck & Co, Inc., and Novartis Pharmaceuticals Corp.; served as a consultant for Dermira, Janssen-Ortho, Inc., Regeneron, and Sun Pharmaceutical Industries, Ltd.; and was a member of a Data Safety Monitoring Board for Eli Lilly and Company. E.M.G.J. de Jong has received research grants for the independent research fund of the Dept. of Dermatology of the Radboud University Medical Center from AbbVie, Janssen, and Pfizer; and has acted as consultant and\/or paid speaker for and\/or participated in research sponsored by companies manufacturing drugs for the treatment of psoriasis, including AbbVie, Amgen, Celgene, Eli Lilly, Janssen, MSD, Novartis, and Pfizer (all funding goes to the independent research fund of \u201cRadboud\u201d). N. H. Shear has been a paid consultant for AbbVie, Actelion, Biogen, Celgene, Janssen, Leo, Lilly, Novartis, and Sanofi. M. Lebwohl is an employee of Mount Sinai, which receives research funds from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen\/Johnson & Johnson, Kadmon, Medimmune\/Astra Zeneca, Novartis, Pfizer, and ViDac. B. Srivastava and L. Hopkins are employees of Janssen Scientific Affairs, LLC, and W. Langholff is an employee of Janssen Research & Development, LLC. A.W. Armstrong has served as investigator, advisor, and\/or consultant to AbbVie, Janssen, Novartis, Lilly, Regeneron, Sanofi, Leo, and Ortho Dermatologics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}